635 related articles for article (PubMed ID: 27842676)
21. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
[TBL] [Abstract][Full Text] [Related]
22. Can high b-value 3.0 T biparametric MRI with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naïve men?
Wang G; Yu G; Chen J; Yang G; Xu H; Chen Z; Wang G; Bai Z
Clin Imaging; 2022 Aug; 88():80-86. PubMed ID: 34243992
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Prostate Imaging Reporting and Data System Classification in the Prediction of Tumor Aggressiveness in Targeted Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy.
Borkowetz A; Platzek I; Toma M; Renner T; Herout R; Baunacke M; Laniado M; Baretton GB; Froehner M; Zastrow S; Wirth MP
Urol Int; 2017; 99(2):177-185. PubMed ID: 28531902
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Performance of PI-RADS v2, Proposed Adjusted PI-RADS v2 and Biparametric Magnetic Resonance Imaging for Prostate Cancer Detection: A Preliminary Study.
Cai GH; Yang QH; Chen WB; Liu QY; Zeng YR; Zeng YJ
Curr Oncol; 2021 May; 28(3):1823-1834. PubMed ID: 34065851
[TBL] [Abstract][Full Text] [Related]
25. Quantitative Apparent Diffusion Coefficient Derived From Diffusion-Weighted Imaging Has the Potential to Avoid Unnecessary MRI-Guided Biopsies of mpMRI-Detected PI-RADS 4 and 5 Lesions.
Polanec SH; Helbich TH; Bickel H; Wengert GJ; Pinker K; Spick C; Clauser P; Susani M; Shariat S; Baltzer PAT
Invest Radiol; 2018 Dec; 53(12):736-741. PubMed ID: 29985792
[TBL] [Abstract][Full Text] [Related]
26. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
27. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.
Radtke JP; Kuru TH; Boxler S; Alt CD; Popeneciu IV; Huettenbrink C; Klein T; Steinemann S; Bergstraesser C; Roethke M; Roth W; Schlemmer HP; Hohenfellner M; Hadaschik BA
J Urol; 2015 Jan; 193(1):87-94. PubMed ID: 25079939
[TBL] [Abstract][Full Text] [Related]
28. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?
Junker D; Steinkohl F; Fritz V; Bektic J; Tokas T; Aigner F; Herrmann TRW; Rieger M; Nagele U
World J Urol; 2019 Apr; 37(4):691-699. PubMed ID: 30078170
[TBL] [Abstract][Full Text] [Related]
29. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
30. Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study.
Hoeks CM; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Roobol MJ; Bul M; Hambrock T; Witjes JA; Fütterer JJ; Hulsbergen-van de Kaa CA; Barentsz JO
Invest Radiol; 2014 Mar; 49(3):165-72. PubMed ID: 24220253
[TBL] [Abstract][Full Text] [Related]
31. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
32. Implementation of a 5-Minute Magnetic Resonance Imaging Screening Protocol for Prostate Cancer in Men With Elevated Prostate-Specific Antigen Before Biopsy.
Weiss J; Martirosian P; Notohamiprodjo M; Kaufmann S; Othman AE; Grosse U; Nikolaou K; Gatidis S
Invest Radiol; 2018 Mar; 53(3):186-190. PubMed ID: 29077588
[TBL] [Abstract][Full Text] [Related]
33. The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer.
Thompson JE; van Leeuwen PJ; Moses D; Shnier R; Brenner P; Delprado W; Pulbrook M; Böhm M; Haynes AM; Hayen A; Stricker PD
J Urol; 2016 May; 195(5):1428-1435. PubMed ID: 26529298
[TBL] [Abstract][Full Text] [Related]
34. The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer.
Cao Y; Cao M; Chen Y; Yu W; Fan Y; Liu Q; Gao G; Zhao Z; Wang X; Jin J
Oncotarget; 2017 Jul; 8(27):44040-44049. PubMed ID: 28476042
[TBL] [Abstract][Full Text] [Related]
35. Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6.
Song W; Bang SH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Kim CK; Lee HM
Clin Genitourin Cancer; 2018 Aug; 16(4):281-287. PubMed ID: 29550198
[TBL] [Abstract][Full Text] [Related]
36. PSA-density does not improve bi-parametric prostate MR detection of prostate cancer in a biopsy naïve patient population.
Cuocolo R; Stanzione A; Rusconi G; Petretta M; Ponsiglione A; Fusco F; Longo N; Persico F; Cocozza S; Brunetti A; Imbriaco M
Eur J Radiol; 2018 Jul; 104():64-70. PubMed ID: 29857868
[TBL] [Abstract][Full Text] [Related]
37. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer.
Lin WC; Westphalen AC; Silva GE; Chodraui Filho S; Reis RB; Muglia VF
Abdom Radiol (NY); 2016 Nov; 41(11):2209-2217. PubMed ID: 27364781
[TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance imaging-guided biopsies may improve diagnosis in biopsy-naive men with suspicion of prostate cancer.
Winther MD; Balslev I; Boesen L; Logager V; Noergaard N; Thestrup KD; Thomsen HS
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552089
[TBL] [Abstract][Full Text] [Related]
39. Added value of diffusion-weighted images and dynamic contrast enhancement in multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer in the PICTURE trial.
Eldred-Evans D; Neves JB; Simmons LAM; Kanthabalan A; McCartan N; Shah TT; Arya M; Charman SC; Freeman A; Moore CM; Punwani S; Emberton M; Ahmed HU
BJU Int; 2020 Mar; 125(3):391-398. PubMed ID: 31733173
[TBL] [Abstract][Full Text] [Related]
40. Prebiopsy biparametric MRI: differences of PI-RADS version 2 in patients with different PSA levels.
Choi MH; Lee YJ; Jung SE; Rha SE; Byun JY
Clin Radiol; 2018 Sep; 73(9):810-817. PubMed ID: 29895386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
